Results 21 to 30 of about 3,688,287 (401)
Clinical and Translational Allergy, 2023 Background House dust mite (HDM) is the most common sensitising allergen in asthma. Ethnic minority groups (EMGs) in the UK are more likely to live in deprived conditionings with a greater exposure to HDM and other aero‐allergens.
Adel H. Mansur +7 more
doaj +1 more source
Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial.
New England Journal of Medicine, 2021 BACKGROUND Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear ...
C. Brightling +4 more
semanticscholar +1 more source
Treating severe asthma: Targeting the IL‐5 pathway
Clinical and Experimental Allergy, 2021 Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)‐4, IL‐5
S. Principe +12 more
semanticscholar +1 more source
Frontiers in Medicine, 2022 BackgroundAtopic dermatitis (AD) is regarded as a chronic systemic disease which is characterized by a robust overexpression of type 2 related cytokines, with increased total IgE levels and a concomitant sensitization to common allergens.
Ruperto González-Pérez +5 more
doaj +1 more source
Obesity, Inflammation, and Severe Asthma: an Update
Current Allergy and Asthma Reports, 2021 Obesity-associated difficult asthma continues to be a substantial problem and, despite a move to address treatable traits affecting asthma morbidity and mortality, it remains poorly understood with limited phenotype-specific treatments.
Varun Sharma, D. Cowan
semanticscholar +1 more source
Imaging for precision medicine: can V‐P SPECT measure mepolizumab response in asthma?
Respirology Case Reports, 2021 Monoclonal antibody therapies are effective for many but not all people with severe asthma. Precision medicine guides treatment selection using biomarkers to select patients most likely to respond according to their inflammatory endotypes.
Vanessa M. McDonald +5 more
doaj +1 more source
Respiratory Medicine Case Reports, 2022 Severe eosinophilic asthma is associated with a high corticosteroid burden, particularly in patients with comorbid chronic sinusitis/nasal polyps. This case study reports a 33-year-old woman who presented to the severe asthma center with uncontrolled ...
Adel H. Mansur, PhD FRCP
doaj +1 more source
Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
Journal of Asthma and Allergy, 2021 Background Having been approved for biological treatment of atopic dermatitis, dupilumab has also been recently licensed as add-on therapy for severe asthma and nasal polyposis.
C. Pelaia +7 more
semanticscholar +1 more source
Application of an algorithm to analyze patterns of intermittent oral corticosteroid use in asthma
npj Primary Care Respiratory Medicine, 2023 An algorithm to describe patterns of intermittent oral corticosteroid use in the UK (n = 476,167) found that one-third of patients receiving intermittent oral corticosteroids for asthma only had short gaps (
John Haughney +11 more
doaj +1 more source
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]
, 2020 BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai +13 more
core +1 more source